Warberg Asset Management’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Warberg Asset Management’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,000	Closed	-$420	–	221
2024 Q2	$420	Hold	30,000	–	–	﹤0.01%	218
2024 Q1	$285	Hold	30,000	–	–	﹤0.01%	212
2023 Q4	$210	Hold	30,000	–	–	﹤0.01%	230
2023 Q3	$525	Hold	30,000	–	–	﹤0.01%	240
2023 Q2	$575	Sell	30,000 -8,069	-21%	-$195	﹤0.01%	234
2023 Q1	$1.32K	Sell	38,069 -22,642	-37%	-$802	﹤0.01%	243
2022 Q4	$1.21K	Sell	60,711 -39,089	-39%	-$1.24K	﹤0.01%	260
2022 Q3	$9K	Sell	99,800 -200	-0.2%	-$20	﹤0.01%	238
2022 Q2	$11K	Hold	100,000	–	–	﹤0.01%	200
2022 Q1	$16K	Buy	100,000 +48,601	+95%	+$13.7K	﹤0.01%	191
2021 Q4	$22K	Sell	51,399 -48,601	-49%	-$38.2K	﹤0.01%	173
2021 Q3	$85K	Buy	+100,000	New	+$103K	0.01%	146

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Warberg Asset Management's DRMAW Position: Q3 2024 in Review

Warberg Asset Management sold out of Dermata Therapeutics Warrant (DRMAW) in Q3 2024, closing a stake of 30,000 shares — an estimated $420 sold.

Warberg Asset Management first reported a position in DRMAW in Q3 2021 and held it in 12 quarters. The position peaked at $85K in Q3 2021. 3 funds tracked by Wall St. Rank hold DRMAW as of Q3 2024.

Warberg Asset Management reported no remaining Dermata Therapeutics Warrant position as of Q3 2024 after selling out during the quarter.
Warberg Asset Management sold 30,000 Dermata Therapeutics Warrant shares in Q3 2024, an estimated $420.
Warberg Asset Management first reported a position in Dermata Therapeutics Warrant in Q3 2021 and held it in 12 quarters.
Warberg Asset Management's Dermata Therapeutics Warrant position peaked at $85K in Q3 2021.
3 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q3 2024.

Based on Warberg Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.